Longeveron Inc. filings document a clinical-stage biotechnology issuer developing laromestrocel, an investigational allogeneic cellular therapy, and its related regulatory, financing, governance, and listing disclosures. Form 8-K reports cover FDA communications, clinical-development updates, material agreements, executive and board compensation matters, shareholder meeting actions, and Nasdaq continued-listing notices.
Registration statements and event reports also identify LGVN’s Class A common stock, Nasdaq Capital Market listing, emerging growth company status, and financing-related securities disclosures. The filing record ties the company’s public-company reporting to clinical and regulatory development of laromestrocel, stockholder voting matters, and capital resources used to fund biotechnology operations.
Longeveron Inc. reported that Nasdaq has notified the company its Class A common stock no longer meets the $1.00 minimum bid price requirement for listing on The Nasdaq Capital Market, based on the stock closing below this level for 30 consecutive business days. The notice does not immediately remove the stock from Nasdaq.
Longeveron has until March 23, 2026 to regain compliance, which would occur if the bid price closes at $1.00 or more for at least 10 consecutive business days, subject to Nasdaq’s discretion to require up to 20 days. If the closing bid price is $0.10 or less for ten consecutive trading days, Nasdaq may move to suspend and delist the stock sooner. The company plans to monitor its share price and consider options to regain compliance but warns there is no assurance it will succeed or meet other Nasdaq listing rules.
Longeveron Inc. filed a Form 8-K reporting a material event: an ATM Agreement dated September 19, 2025 between Longeveron Inc. and H.C. Wainwright & Co., LLC. The filing lists accompanying legal items including an opinion and consent from Buchanan Ingersoll & Rooney PC, and an interactive data file. The document is signed by Than Powell, Chief Executive Officer. The submission indicates the company has executed the arrangements needed to access at-the-market equity sales under the named agreement, with counsel opinion and consent included as exhibits.
Longeveron Inc. is offering up to 33,655,871 shares of Class A common stock in an at-the-market offering, assuming sale of 14,078,947 shares at $0.76 per share. Proceeds are intended to fund clinical and regulatory development of its lead stem-cell therapy laromestrocel (Lomecel-B) across hypoplastic left heart syndrome (HLHS), mild Alzheimer’s disease (AD) and pediatric dilated cardiomyopathy (DCM), plus manufacturing, regulatory and general corporate needs. Key clinical milestones include the ELPIS II Phase 2b HLHS trial, now fully enrolled with anticipated top-line results in Q3 2026 and a potential BLA filing in late 2026 if successful; Phase 2a CLEAR MIND in mild AD met its primary safety endpoint and showed nominal significance on a secondary cognitive composite with MRI signals of preserved brain volumes including left hippocampus; FDA approved an IND for pediatric DCM on July 8, 2025 with Phase 2 pivotal plans in H1 2026 subject to financing. The company discontinued its Japan frailty trial in April 2024 but continues Bahamas registries and plans an osteoarthritis registry. Net tangible book value per Class A share was $0.62 as of June 30, 2025 and pro forma values are modestly higher. The prospectus highlights typical biotech risks including need for additional capital, regulatory and clinical uncertainties, potential dilution from outstanding warrants, options and convertible shares, and governance provisions such as a dual-class structure and board authority that may limit shareholder actions.
Longeveron Inc. reported a leadership change. On August 27, 2025, Chief Executive Officer Wa’el Hashad stepped down as CEO and as a member of the Board of Directors to pursue other opportunities. The Board appointed Than Powell, currently Chief Business Officer and head of business development, to serve as interim Chief Executive Officer effective September 4, 2025, until a permanent successor is identified.
The Board also named company founder and Chief Science Officer Dr. Joshua Hare as Executive Chairman. As interim CEO, Mr. Powell will receive a base salary of $500,000, a potential prorated target bonus equal to 60% of base salary, and an equity grant of restricted stock units and stock options, subject to vesting. The company states there are no arrangements or related‑party transactions influencing Mr. Powell’s selection for this role.
Lincoln Alternative Strategies LLC reports beneficial ownership of 1,176,470 shares of Longeveron Inc. Class A common stock, representing 6.09% of the class based on 19,312,218 shares outstanding as of August 8, 2025. The filing states Lincoln Alternative has sole voting and dispositive power over these shares and disclaims acquisition for the purpose of changing or influencing control of the issuer.
The statement provides the filer’s Delaware organization and business address in Miami Beach, Florida, and class/CUSIP details for clarity. No transactions, arrangements, or group affiliations are reported in this filing.
Longeveron Inc. reporting persons Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC disclose shared beneficial ownership equal to 2,143,418 shares of Class A common stock, representing approximately 9.99% of the class as of August 15, 2025. The holdings are issuable upon exercise of Intracoastal Warrant 1 and are subject to blocker provisions that limit exercise to prevent exceeding specified ownership thresholds (9.99% or 4.99% depending on the warrant). The filing specifies no sole voting or dispositive power and that the positions are not held to change or influence control of the issuer.
Lisa Locklear, identified on the Form 4 as Chief Financial Officer and a director of Longeveron Inc. (LGVN), made a direct purchase on 08/11/2025 of 11,766 shares of Class A common stock. Each purchased share was accompanied by two and one-half Class A common warrants, for a total of 29,415 warrants, and the combined purchase price for each share plus accompanying warrants was $0.85. Following the reported transaction, Ms. Locklear directly beneficially owned 250,964 shares of Class A common stock.
The warrants are shown with an exercise/conversion price of $0.85 and an expiration date of 08/11/2027, and the reported holdings and transactions are recorded as direct ownership on the Form 4.
Baluch Khoso, a director of Longeveron Inc. (LGVN), reported an insider purchase on 08/11/2025. The filing shows he acquired 11,766 Class A common shares together with 29,415 Class A common warrants at a combined purchase price of $0.85 per share-plus-warrants package. After the transaction, the report lists 52,516 Class A common shares beneficially owned directly.
The warrants are exercisable immediately and expire on 08/11/2027. The Form 4 was signed by an attorney-in-fact on 08/13/2025.
Longeveron Inc. furnished a current report describing that it has released a press release with its financial and operating results for the three and six months ended June 30, 2025, along with other business updates and information. The press release is attached as an exhibit and is incorporated by reference for details on revenue, expenses, and operational progress. The company specifies that this information is being furnished, not filed, which affects how it is treated under securities laws but still provides shareholders with an update on recent performance and developments.
Longeveron Inc. (LGVN) reported unaudited results for the quarter ended June 30, 2025 showing continued clinical-stage operations with rising costs and constrained liquidity. Cash and cash equivalents declined to $10.3 million from $19.2 million at year-end, and the company recorded a $10.0 million net loss for the six months ended June 30, 2025, widening from $7.5 million a year earlier. Revenue for the six months was $0.7 million, down from $1.0 million, while research and development and general and administrative expenses increased, driving an operating loss of $10.6 million for the period.
The company disclosed a $119.6 million accumulated deficit and stated it does not have sufficient cash to meet minimum expenditures for one year without additional financing, creating substantial doubt about its ability to continue as a going concern. Management cites completed financing activity and expects current cash to fund operations into the first quarter of 2026 based on its budget. Regulatory progress includes a Type C FDA meeting for the HLHS pathway and a Type B FDA meeting for Alzheimer’s, and the company is ramping BLA-enabling and manufacturing readiness activities, contingent on trial success and additional funding.